Compounded prescriptions get audited on their own track. A standard dispensing claim carries one NDC and one price. A compounded claim can carry a dozen or more, each ingredient billed as its own line with its own quantity and cost, and each one a separate point of failure in a PBM audit. A pharmacy that compounded and dispensed the prescription exactly as written can still face a six-figure recoupment if the invoice behind a single ingredient does not tie out. OptumRx, CVS Caremark, Express Scripts, Humana, and Prime Therapeutics each run compound-specific documentation demands that go beyond what a routine dispensing audit calls for.
How PBMs Price Compound Ingredients
A compound claim is not billed as one product. It is billed ingredient by ingredient, each with its own valid NDC, its own metric quantity, and its own cost, then summed to a total compounded amount. CVS Caremark's own claim guidance requires the 11-digit NDC, ingredient name, metric quantity, and cost for every ingredient in a multi-ingredient compound, plus the total compounded quantity and the total dollar amount paid. When a compound claim is later audited or appealed, OptumRx's own appeal guidance states that the submitted per-unit drug acquisition cost must be the pharmacy's lowest per-unit cost for that ingredient during the claim period, net of any rebates and discounts from the supplier or manufacturer, and limited to ingredient cost alone, excluding any pharmacy service fee. OptumRx reserves the right to request supplier and manufacturer invoices and to validate acquisition cost against them.
The Documentation a Compound Claim Requires
A defensible compound claim rests on records that sit outside the claims system entirely. The master formulation record sets out the formula and procedure for a given preparation; the compounding record documents each batch actually made, including lot numbers, quantities used, and the beyond-use date assigned. PBM audit teams increasingly pair that request with Drug Supply Chain Security Act transaction documentation. Frier Levitt has tracked a rise in PBM audits seeking DSCSA “T3” documentation, the transaction information, history, and statement a pharmacy must obtain from a licensed supplier before an ingredient enters inventory, and has reported that missing or inaccurate documentation on that chain has already led to claim chargebacks and network termination in some audits. Whether the pharmacy compounds under 503A or receives finished preparations from a 503B outsourcing facility bound by cGMP standards changes which of these records the pharmacy is expected to hold and produce on demand.
Where Recoupment Findings Come From
Most compound recoupments trace back to a mismatch, not a dispensing error. An audit team reconciles the NDC and quantity billed on the claim against the NDC and quantity on the supplier invoice; if the ingredient billed does not match what was purchased, or the quantity billed exceeds what the pharmacy's purchase history supports, the difference becomes an inventory shortfall finding on that ingredient alone. A missing or incomplete compounding record can support a separate finding, independent of whether the preparation was clinically appropriate. Sterile and hazardous compounds carry an added layer: a pharmacy compounding under USP 797/800 that cannot produce its environmental and personnel documentation faces overlapping exposure, since a PBM recoupment on a sterile compound often tracks a parallel state board of pharmacy inquiry into the same preparation. High-volume categories such as semaglutide and tirzepatide preparations draw disproportionate audit attention precisely because their ingredient costs and sourcing chains are the easiest for a PBM to test against shortage-era compounding records.
A compound claim is only as defensible as its least-documented ingredient, and a PBM audit team is trained to find that ingredient first.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice or recoupment demand tied to compounded claims. Early legal intervention can protect the pharmacy's rights, ensure the response addresses each ingredient-level finding on its documentary merits, avoid inadvertent admissions, preserve every available defense, and allow counsel to communicate with the auditor on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of the audit and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies against PBM audits, ingredient-level recoupment demands, and network terminations across OptumRx, CVS Caremark, Express Scripts, Humana, and Prime Therapeutics. With 25+ years of combined experience defending pharmacy audits, our team knows which ingredient-level findings hold up and which do not. If your pharmacy is facing a PBM audit or recoupment demand tied to compounded claims, contact us for a free, confidential consultation.
